

**Ribavirin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

---

**SECTION 1: Identification of the substance/mixture and of the company/undertaking****1.1 Product identifier**

Trade name : Ribavirin Solid Formulation

**1.2 Relevant identified uses of the substance or mixture and uses advised against**

Use of the Sub-  
stance/Mixture : Pharmaceutical

Recommended restrictions : Not applicable  
on use

**1.3 Details of the supplier of the safety data sheet**

Company : MSD  
117 16th Road  
1685 Halfway house, Midrand, South Africa

Telephone : +27 11 655 3000

E-mail address of person : EHSDATASTEWARD@msd.com  
responsible for the SDS

**1.4 Emergency telephone number**

+1-908-423-6000

---

**SECTION 2: Hazards identification****2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Germ cell mutagenicity, Category 2  
Reproductive toxicity, Category 1B

Specific target organ toxicity - single ex-  
posure, Category 3

Specific target organ toxicity - repeated  
exposure, Category 1

H341: Suspected of causing genetic defects.

H360Df: May damage the unborn child. Suspected  
of damaging fertility.

H335: May cause respiratory irritation.

H372: Causes damage to organs through pro-  
longed or repeated exposure.

**2.2 Label elements****Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms :



Signal word : Danger

## Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

Hazard statements : H335 May cause respiratory irritation.  
 H341 Suspected of causing genetic defects.  
 H360Df May damage the unborn child. Suspected of damaging fertility.  
 H372 Causes damage to organs through prolonged or repeated exposure.

Precautionary statements : **Prevention:**  
 P201 Obtain special instructions before use.  
 P260 Do not breathe dust.  
 P264 Wash skin thoroughly after handling.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.  
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label:

Ribavirin

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Ribavirin	36791-04-5	Acute Tox. 4; H302 Muta. 2; H341 Repr. 1B; H360Df STOT SE 3; H335 STOT RE 1; H372 (Blood)	>= 50 - < 70

For explanation of abbreviations see section 16.

**Ribavirin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

**SECTION 4: First aid measures****4.1 Description of first aid measures**

- |                            |   |   |
|----------------------------|---|---|
| General advice             | : | In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice.  |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).   |
| If inhaled                 | : | If inhaled, remove to fresh air.<br>Get medical attention.  |
| In case of skin contact    | : | In case of contact, immediately flush skin with soap and plenty of water.<br>Remove contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse. |
| In case of eye contact     | : | If in eyes, rinse well with water.<br>Get medical attention if irritation develops and persists.  |
| If swallowed               | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.   |

**4.2 Most important symptoms and effects, both acute and delayed**

- |       |   |   |
|-------|---|---|
| Risks | : | Contact with dust can cause mechanical irritation or drying of the skin.<br>Dust contact with the eyes can lead to mechanical irritation.<br><br>May cause respiratory irritation.<br>Suspected of causing genetic defects.<br>May damage the unborn child. Suspected of damaging fertility.<br>Causes damage to organs through prolonged or repeated exposure. |
|-------|---|---|

**4.3 Indication of any immediate medical attention and special treatment needed**

- |           |   |   |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

**SECTION 5: Firefighting measures****5.1 Extinguishing media**

- |                              |   |  |
|------------------------------|---|--|
| Suitable extinguishing media | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical |
|------------------------------|---|--|

**Ribavirin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

---

Unsuitable extinguishing media : None known.

**5.2 Special hazards arising from the substance or mixture**

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Metal oxides

**5.3 Advice for firefighters**

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

**SECTION 6: Accidental release measures****6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**6.2 Environmental precautions**

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

**6.3 Methods and material for containment and cleaning up**

Methods for cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air.  
Add excess liquid to allow the material to enter into solution.  
Soak up with inert absorbent material.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and dis-

**Ribavirin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

---

posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**6.4 Reference to other sections**

See sections: 7, 8, 11, 12 and 13.

---

**SECTION 7: Handling and storage****7.1 Precautions for safe handling**

- |                         |   |   |
|-------------------------|---|---|
| Technical measures      | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.  |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.   |
| Advice on safe handling | : | Do not get on skin or clothing.<br>Do not breathe dust.<br>Do not swallow.<br>Avoid contact with eyes.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Keep container tightly closed.<br>Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Take precautionary measures against static discharges.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.  |

**7.2 Conditions for safe storage, including any incompatibilities**

- |   |   |  |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations. |
| Advice on common storage                      | : | Do not store with the following product types:   |

## Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

**7.3 Specific end use(s)**

Specific use(s) : No data available

**SECTION 8: Exposure controls/personal protection****8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Ribavirin	36791-04-5	Wipe limit	400 µg/100 cm <sup>2</sup>	Internal
		TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
Cellulose	9004-34-6	OEL-RL	10 mg/m <sup>3</sup>	ZA OEL
Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents				

**8.2 Exposure controls****Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

**Personal protective equipment**

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the rec-

**Ribavirin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

Filter type : Recommended guidelines, use respiratory protection.  
: Particulates type (P)

**SECTION 9: Physical and chemical properties****9.1 Information on basic physical and chemical properties**

Appearance	: powder
Colour	: white
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: Not applicable
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: Not applicable
Relative vapour density	: Not applicable
Relative density	: No data available
Density	: No data available
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: Not applicable
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.

**Ribavirin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

---

**9.2 Other information**

Particle size : No data available

---

**SECTION 10: Stability and reactivity****10.1 Reactivity**

Not classified as a reactivity hazard.

**10.2 Chemical stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

**10.4 Conditions to avoid**

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

**10.5 Incompatible materials**

Materials to avoid : Oxidizing agents

**10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

---

**SECTION 11: Toxicological information****11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg  
Method: Calculation method

**Components:****Ribavirin:**

Acute oral toxicity : LD50 (Rat): 4.116 - 5.584 mg/kg  
LD50 (Mouse): > 10.000 mg/kg  
LD50 (Dog): >= 1.500 mg/kg



## Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

---

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): 1.554 - 1.758 mg/kg  
Application Route: Intraperitoneal

LD50 (Mouse): 1.268 mg/kg  
Application Route: Intraperitoneal

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Ribavirin:**

Remarks : No data available  
May irritate skin.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Ribavirin:**

Remarks : No data available  
May irritate eyes.

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Ribavirin:**

Remarks : No data available

**Germ cell mutagenicity**

Suspected of causing genetic defects.

**Components:****Ribavirin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Rodent cell line  
Result: positive

## Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

---

Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: negative

Genotoxicity in vivo : Test Type: dominant lethal test  
Species: Rat  
Result: negative

Test Type: Mouse Lymphoma  
Species: Mouse  
Result: positive

Test Type: Micronucleus test  
Species: Mouse  
Result: positive

Germ cell mutagenicity- Assessment : Positive result(s) from in vivo mammalian somatic cell mutagenicity tests.

**Carcinogenicity**

Not classified based on available information.

**Components:****Ribavirin:**

Species : Mouse  
Application Route : Oral  
Exposure time : 6 Months  
LOAEL : 75 mg/kg body weight  
Result : negative  
Target Organs : Blood, Testes  
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 10 mg/kg body weight  
Result : negative  
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Mouse  
Application Route : Oral  
Exposure time : 18 Months  
Result : negative  
Remarks : The mechanism or mode of action may not be relevant in humans.

**Reproductive toxicity**

May damage the unborn child. Suspected of damaging fertility.

**Ribavirin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

---

**Components:****Ribavirin:**

## Effects on fertility

: Test Type: Fertility  
Species: Rat, male  
Application Route: Intraperitoneal injection  
Fertility: LOAEL: < 20 mg/kg body weight  
Symptoms: Reduced fertility  
Result: positive

Test Type: Fertility  
Species: Mouse, male  
Application Route: Oral  
Fertility: LOAEL: 35 mg/kg body weight  
Symptoms: Reduced fertility  
Result: positive

Test Type: Fertility  
Species: Rat, females  
Application Route: Oral  
Fertility: NOAEL: 10 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility  
Species: Rat, male  
Application Route: Oral  
Fertility: NOAEL: 160 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

## Effects on foetal development

: Test Type: Development  
Species: Rat, female  
Application Route: Oral  
Developmental Toxicity: LOAEL: <= 1 mg/kg body weight  
Symptoms: Reduced body weight, Reduced number of viable fetuses, Skeletal malformations  
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Development  
Species: Rabbit, female  
Application Route: Oral  
General Toxicity Maternal: LOAEL: 1 mg/kg body weight  
Developmental Toxicity: LOAEL: 1 mg/kg body weight  
Symptoms: Reduced body weight, Skeletal malformations  
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Development  
Species: Hamster  
Application Route: Oral  
Developmental Toxicity: LOAEL: 2,5 mg/kg body weight  
Symptoms: Skeletal and visceral variations, Total Resorptions / resorption rate  
Result: Embryotoxic effects and adverse effects on the offspring were detected.

**Ribavirin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

---

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 0,3 mg/kg body weight  
Embryo-foetal toxicity: LOAEL: 1 mg/kg body weight  
Symptoms: Skeletal malformations  
Result: positive

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

May cause respiratory irritation.

**Components:****Ribavirin:**

Assessment : May cause respiratory irritation.

**STOT - repeated exposure**

Causes damage to organs through prolonged or repeated exposure.

**Components:****Ribavirin:**

Exposure routes : Ingestion  
Target Organs : Blood  
Assessment : Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Ribavirin:**

Species : Monkey  
LOAEL : 30 mg/kg  
Exposure time : 10 d  
Target Organs : Blood, Gastrointestinal tract

Species : Rat  
NOAEL : 7,6 mg/kg  
Application Route : Inhalation  
Exposure time : 90 d  
Target Organs : Blood, Lungs

Species : Dog  
NOAEL : 5 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Target Organs : Blood, Gastrointestinal tract

**Ribavirin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

Species	:	Mouse
NOAEL	:	20 mg/kg
Application Route	:	Oral
Exposure time	:	18 Months
Target Organs	:	Blood, Cardio-vascular system

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Ribavirin:**

Inhalation	:	Symptoms: Headache, Dizziness Remarks: Based on Human Evidence
Skin contact	:	Remarks: May cause eye irritation. Based on Human Evidence
Eye contact	:	Remarks: May cause eye irritation. Based on Human Evidence
Ingestion	:	Symptoms: blood effects, immune system effects, anorexia, Dizziness, insomnia, Fatigue, Headache, Itching, Rash, liver function change, Gastrointestinal disturbance

**SECTION 12: Ecological information****12.1 Toxicity****Components:****Ribavirin:**

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 119 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 117 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 119 mg/l Exposure time: 96 h Method: OECD Test Guideline 201  NOEC (Pseudokirchneriella subcapitata (green algae)): 6,9 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	EC50 : > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

**Ribavirin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

---

**12.2 Persistence and degradability**

No data available

**12.3 Bioaccumulative potential****Components:****Ribavirin:**Partition coefficient: n- : log Pow: 0,971  
octanol/water**12.4 Mobility in soil**

No data available

**12.5 Results of PBT and vPvB assessment****Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

**12.6 Other adverse effects****Product:**Endocrine disrupting poten- : The substance/mixture does not contain components consid-  
tial : ered to have endocrine disrupting properties according to  
REACH Article 57(f) or Commission Delegated regulation  
(EU) 2017/2100 or Commission Regulation (EU) 2018/605 at  
levels of 0.1% or higher.

---

**SECTION 13: Disposal considerations****13.1 Waste treatment methods**

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

**SECTION 14: Transport information****14.1 UN number**

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good

## Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

---

IATA : Not regulated as a dangerous good

**14.2 UN proper shipping name**

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

**14.3 Transport hazard class(es)**

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

**14.4 Packing group**

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA (Cargo) : Not regulated as a dangerous good

IATA (Passenger) : Not regulated as a dangerous good

**14.5 Environmental hazards**

Not regulated as a dangerous good

**14.6 Special precautions for user**

Not applicable

**14.7 Transport in bulk according to Annex II of Marpol and the IBC Code**

Remarks : Not applicable for product as supplied.

---

**SECTION 15: Regulatory information****15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

## Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

**15.2 Chemical safety assessment**

A Chemical Safety Assessment has not been carried out.

**SECTION 16: Other information**

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Full text of H-Statements**

H302 : Harmful if swallowed.  
 H335 : May cause respiratory irritation.  
 H341 : Suspected of causing genetic defects.  
 H360Df : May damage the unborn child. Suspected of damaging fertility.  
 H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.

**Full text of other abbreviations**

Acute Tox. : Acute toxicity  
 Muta. : Germ cell mutagenicity  
 Repr. : Reproductive toxicity  
 STOT RE : Specific target organ toxicity - repeated exposure  
 STOT SE : Specific target organ toxicity - single exposure  
 ZA OEL : South Africa. The Regulations for Hazardous Chemical Agents, Occupational Exposure Limits  
 ZA OEL / OEL-RL : Occupational Exposure Limit Restricted limit - 8- hour exposure or equivalent (12 hour shifts)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Re-



## Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
3.2	14.04.2025	402661-00022	Date of first issue: 11.12.2015

striction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Classification of the mixture:**

Muta. 2	H341
Repr. 1B	H360Df
STOT SE 3	H335
STOT RE 1	H372

**Classification procedure:**

Calculation method
Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN